Echo Therapeutics, Inc. (OTCMKTS:ECTE) Files An 8-K Other EventsItem 8.01 Other Events.
Echo Therapeutics, Inc. (OTCMKTS:ECTE) Files An 8-K Other Events
On December 21, 2016, Echo Therapeutics, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1
Press Release, dated December 21, 2016.
About Echo Therapeutics, Inc. (OTCMKTS:ECTE)
Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States. Echo Therapeutics, Inc. (OTCMKTS:ECTE) Recent Trading Information
Echo Therapeutics, Inc. (OTCMKTS:ECTE) closed its last trading session 00.000 at 0.214 with 313,339 shares trading hands.
Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States. Echo Therapeutics, Inc. (OTCMKTS:ECTE) Recent Trading Information
Echo Therapeutics, Inc. (OTCMKTS:ECTE) closed its last trading session 00.000 at 0.214 with 313,339 shares trading hands.
